Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Daiichi Sankyo
Novartis
McKesson
Argus Health
Colorcon
Chubb
Cipla
Fuji
Dow

Generated: August 18, 2017

DrugPatentWatch Database Preview

EPANOVA Drug Profile

« Back to Dashboard

What is the patent landscape for Epanova, and when can generic versions of Epanova launch?

Epanova is a drug marketed by Astrazeneca Pharms and is included in one NDA. There are eight patents protecting this drug.

This drug has seventy-four patent family members in thirty-seven countries.

The generic ingredient in EPANOVA is omega-3-carboxylic acids. There is one drug master file entry for this compound. Additional details are available on the omega-3-carboxylic acids profile page.

Summary for Tradename: EPANOVA

Patents:8
Applicants:1
NDAs:1
Clinical Trials: see list15
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:EPANOVA at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms
EPANOVA
omega-3-carboxylic acids
CAPSULE;ORAL205060-001May 5, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Astrazeneca Pharms
EPANOVA
omega-3-carboxylic acids
CAPSULE;ORAL205060-001May 5, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Astrazeneca Pharms
EPANOVA
omega-3-carboxylic acids
CAPSULE;ORAL205060-001May 5, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Astrazeneca Pharms
EPANOVA
omega-3-carboxylic acids
CAPSULE;ORAL205060-001May 5, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Astrazeneca Pharms
EPANOVA
omega-3-carboxylic acids
CAPSULE;ORAL205060-001May 5, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: EPANOVA

Country Document Number Estimated Expiration
Germany602005019402► Subscribe
Poland184085► Subscribe
World Intellectual Property Organization (WIPO)2005079853► Subscribe
Australia5895596► Subscribe
Spain2344208► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Dow
Covington
AstraZeneca
Fuji
Daiichi Sankyo
US Department of Justice
Merck
QuintilesIMS
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot